Welcome to our dedicated page for HALOZYME THERAPEUTICS SEC filings (Ticker: HALO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Halozyme Therapeutics, Inc. filings document the company's drug-delivery business, royalty-based collaboration model, governance actions and capital-market disclosures. 8-K reports cover financial results and guidance, executive officer appointments and compensation arrangements, bylaw amendments, and annual meeting voting results.
Proxy materials describe board elections, executive compensation, equity awards, auditor ratification and stockholder voting mechanics. Filings also provide formal disclosure around ENHANZE, Hypercon and Surf Bio technology portfolio updates, partnered commercial products, and acquisition-related operating updates when reported by the company.
Halozyme Therapeutics reported strong first-quarter 2026 results, with total revenues of $376,708 thousand driven mainly by royalties of $240,681 thousand and product sales of $130,424 thousand. Net income rose to $150,049 thousand, with basic earnings per share of $1.27 and diluted earnings per share of $1.22.
Operating income reached $184,517 thousand as operating expenses increased with higher cost of sales, amortization and research and development. Cash and cash equivalents grew to $309,749 thousand, while total assets were $2,672,719 thousand and total liabilities $2,453,083 thousand, reflecting significant long-term debt. Recent acquisitions added goodwill of $582,323 thousand and intangible assets of $951,955 thousand.
Halozyme Therapeutics reported strong first quarter 2026 results and announced a major new share buyback. Total revenue rose 42% year over year to $376.7 million, driven mainly by 43% royalty growth to $240.7 million and higher product sales.
Net income increased to $150.0 million, with GAAP diluted EPS of $1.22 versus $0.93 a year ago. Non-GAAP diluted EPS rose to $1.60 from $1.11, and adjusted EBITDA reached $229.5 million versus $162.0 million. Cash and investments grew to $320.9 million as of March 31, 2026.
The company approved a new $1 billion share repurchase program, projecting at least $400 million of repurchases in 2026, and reiterated full-year 2026 guidance, including total revenue of $1.71–$1.81 billion, royalty revenue of $1.13–$1.17 billion and non-GAAP EPS of $7.75–$8.25. New collaboration and license deals with GSK, Vertex and Oruka, plus multiple partner approvals and trial milestones, expand the future ENHANZE and Hypercon royalty pipeline.
HALOZYME THERAPEUTICS, INC. director Matthew L. Posard received equity awards as part of the company’s director compensation program. He was granted 3,796 restricted stock units, each representing one future share of common stock, and options for 6,040 shares at an exercise price of $65.87 per share.
The RSUs and options vest in full on the earlier of May 5, 2027 or the next annual meeting of stockholders. The RSUs are subject to a deferral election so shares are delivered when he completes his service as a director. After these grants, he directly holds 77,835 common shares.
HALOZYME THERAPEUTICS, INC. director Mahesh Krishnan received equity awards consisting of common stock and stock options as part of the company’s director compensation program. He acquired 3,796 shares of common stock at no cash cost through a restricted stock unit grant.
He was also granted options to purchase 6,040 shares of common stock at an exercise price of $65.87 per share, expiring on May 5, 2036. Both the RSUs and options vest in full on the earlier of May 5, 2027 or the company’s next annual meeting of stockholders. After these grants, he directly holds 14,462 shares of common stock.
Halozyme Therapeutics director James Paul Lang received equity awards as part of the company’s director compensation program. He was granted 3,796 restricted stock units, each representing one share of common stock, bringing his direct common stock holdings to 4,685 shares.
Lang also received options to purchase 6,040 shares of common stock at an exercise price of $65.87 per share, expiring on May 5, 2036. Both the RSUs and options vest in full on the earlier of May 5, 2027 or the next annual stockholder meeting, with RSU settlement deferred until completion of his board service.
Henderson Jeffrey William reported acquisition or exercise transactions in this Form 4 filing.
HALOZYME THERAPEUTICS director Jeffrey William Henderson received equity compensation in the form of stock and options. He was granted 3,796 restricted stock units, each representing one share of common stock, and an option to purchase 6,040 shares at $65.87 per share.
The RSU and stock option grants are part of the company’s director compensation program. Both awards vest in full on the earlier of May 5, 2027 or the date of the company’s next annual meeting of stockholders. Following the grants, he directly holds 36,572 shares of common stock.
HALOZYME THERAPEUTICS, INC. director Barbara Gayle Duncan received equity compensation in the form of restricted stock units and stock options. She was granted 3,796 shares of common stock as annual RSUs and an option for 6,040 shares of common stock.
The RSUs and options are part of the issuer's director compensation program and each RSU represents one share of common stock. Both awards vest in full on the earlier of May 5, 2027 or the date of the next annual meeting of stockholders. Following the RSU grant, she holds 23,715 common shares directly, and the new option has an exercise price of $65.87 per share and expires on May 5, 2036.
HALOZYME THERAPEUTICS, INC. director Bernadette Connaughton received equity compensation awards on May 5, 2026. She was granted 6,796 restricted stock units (RSUs), each representing one share of common stock, and a stock option for 6,040 shares at an exercise price of $65.87 per share.
Both the RSU grant and the option grant will vest in full on the earlier of May 5, 2027 or the date of the company’s next annual meeting of stockholders. Following the RSU award, Connaughton directly holds 45,294 shares of common stock.
Halozyme Therapeutics, Inc. reported the results of its Annual Meeting of Stockholders held on May 5, 2026. Of 118,474,300 common shares outstanding as of the record date, 104,138,244 shares were represented, meaning a large majority of shareholders participated.
Stockholders elected Bernadette Connaughton and Matthew L. Posard as Class I directors for three-year terms, with each receiving more than a majority of the outstanding shares. They also approved, on an advisory basis, the compensation of the company’s named executive officers and ratified the selection of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026.
HALOZYME THERAPEUTICS, INC. director Bernadette Connaughton sold 1,625 shares of common stock in an open-market transaction at $63.48 per share. After this sale, she directly holds 38,498 shares. The filing notes the sale was made under a pre-arranged Rule 10b5-1 trading plan, indicating it was scheduled in advance.